Oppenheimer maintains Kyntra Bio at Outperform, lowers price target to $30 from $35
Oppenheimer kept Kyntra Bio's rating at Outperform but reduced its price target to $30 from $35, a 14.3% cut. This implies an 837.5% upside from the Nov 16 close of $3.20, according to the firm.

